Drug intelligence / Profile preview

Biovaginil

Development stage
Unknown
Lead developer
NTC Pharma
Modality
Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral, Sublingual
01

Overview

Biovaginil is a probiotic-based food supplement developed by NTC S.r.l., containing the specific strain *Lactobacillus crispatus* NTCVAG04 and vitamin A. It is designed to rebalance the vaginal microbiota and is investigated for the prevention and treatment of bacterial vaginitis and vaginosis. The NTCVAG04 strain is associated with a healthy vaginal environment, characterized by low pH and the absence of infection markers like clue cells or a positive whiff test. Vitamin A is included to maintain the structural integrity and function of the vaginal mucous membranes. The product is administered orally as sublingual granules, intended to promote the restoration of healthy vaginal flora through distal colonization or systemic support of mucosal health.

Brand names
Biovaginil
Other names
lactobacillus crispatus NTCVAG04 + vitamin A
02

Targets

RAR (Retinoic acid receptor)

Beyond the preview

Go deeper on Biovaginil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biovaginil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call